Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin <10g/dL). Patients (n=29; 18 RBC-transfusion dependent) received 0.5 mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21%) patients respond...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Daver, Naval, Shastri, Aditi, Kadia, Tapan, Newberry, Kate, Pemmaraju, Naveen, Jabbour, Elias, Zhou, Linghsa, Pierce, Sherry, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2014
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4157096/
https://ncbi.nlm.nih.gov/pubmed/25047979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2014.06.015
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge